Early weight loss with liraglutide 3.0 mg is a good predictor of clinically meaningful weight loss after 56 weeks

This subgroup analysis of SCALE Obesity and Prediabetes and SCALE Diabetes reports key outcomes in adults achieving ≥5% WL from baseline at Week (W) 16 on liraglutide 3.0 mg (early responders; ER), compared to those who did not (early non-responders; ENR). 2910 adults (2487 without T2D, 423 with T2D) were randomised to liraglutide 3.0 mg with diet & exercise (D&E); 365 with T2D and 2159 without T2D completed to 16W. Efficacy data (LS means/estimated proportions) are for 56W completers. 67.5% of W16 completers without T2D were ER to liraglutide 3.0 mg; mean W56 WL was 11.5%. Proportions of ER with ≥5%, > 10% and…